DK3638251T3 - Bisphosphocin gel formuleringer og brug deraf - Google Patents
Bisphosphocin gel formuleringer og brug deraf Download PDFInfo
- Publication number
- DK3638251T3 DK3638251T3 DK18816615.1T DK18816615T DK3638251T3 DK 3638251 T3 DK3638251 T3 DK 3638251T3 DK 18816615 T DK18816615 T DK 18816615T DK 3638251 T3 DK3638251 T3 DK 3638251T3
- Authority
- DK
- Denmark
- Prior art keywords
- bisphosphocine
- gel formulations
- formulations
- gel
- bisphosphocine gel
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762518262P | 2017-06-12 | 2017-06-12 | |
PCT/US2018/037151 WO2018231863A1 (en) | 2017-06-12 | 2018-06-12 | Bisphosphocin gel formulations and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3638251T3 true DK3638251T3 (da) | 2024-05-13 |
Family
ID=64562861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18816615.1T DK3638251T3 (da) | 2017-06-12 | 2018-06-12 | Bisphosphocin gel formuleringer og brug deraf |
Country Status (13)
Country | Link |
---|---|
US (4) | US11096954B2 (da) |
EP (2) | EP3638251B1 (da) |
JP (2) | JP7148994B2 (da) |
KR (2) | KR20200014904A (da) |
CN (1) | CN110753549A (da) |
AU (3) | AU2018282905B2 (da) |
BR (2) | BR122021011439B1 (da) |
CA (1) | CA3066722A1 (da) |
DK (1) | DK3638251T3 (da) |
FI (1) | FI3638251T3 (da) |
MX (1) | MX2019014772A (da) |
PT (1) | PT3638251T (da) |
WO (1) | WO2018231863A1 (da) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
KR101432466B1 (ko) | 2005-04-15 | 2014-08-21 | 클라루스 쎄러퓨틱스, 아이엔씨. | 소수성 약물의 약물전달시스템 및 이를 포함하는 조성물 |
US11795192B2 (en) | 2017-03-10 | 2023-10-24 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
KR102684529B1 (ko) * | 2017-03-10 | 2024-07-12 | 레이크우드 아메덱스, 인크. | 항미생물 화합물, 조성물, 및 그의 용도 |
US12030908B2 (en) | 2017-03-10 | 2024-07-09 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
US11377468B2 (en) | 2017-03-10 | 2022-07-05 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
EP3866810A4 (en) * | 2018-10-17 | 2022-07-27 | Lakewood Amedex, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ORAL MUCOSITIS |
WO2023004130A1 (en) * | 2021-07-22 | 2023-01-26 | Lakewood Amedex, Inc. | Methods for preparing bisphosphocins |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4105782A (en) | 1975-03-07 | 1978-08-08 | Yu Ruey J | Treatment of acne and dandruff |
SE8004580L (sv) * | 1980-06-19 | 1981-12-20 | Draco Ab | Farmaceutisk beredning |
KR830005852A (ko) * | 1980-07-18 | 1983-09-14 | 미첼 페터 잭슨 | 피부와 점막의 비루스 감염치료에 적합한 국소치료제의 제조방법 |
US4421769A (en) * | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
DE3542516A1 (de) | 1985-12-02 | 1987-06-04 | Henkel Kgaa | Desinfektionsmittel |
DE3731255A1 (de) * | 1987-09-17 | 1989-04-06 | Boehringer Ingelheim Int | Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen |
US5153230A (en) | 1989-10-06 | 1992-10-06 | Perfective Cosmetics, Inc. | Topical skin cream composition |
US5167950A (en) * | 1991-03-28 | 1992-12-01 | S. C. Johnson & Son | High alcohol content aerosol antimicrobial mousse |
US5208015A (en) * | 1991-07-23 | 1993-05-04 | Bristol-Myers Squibb Company | Topical anti-fungal agents having anti-inflammatory activity |
DE4333385C2 (de) | 1993-09-30 | 1997-01-30 | Friedrich A Spruegel | Flächendesinfektions- und Reinigungsmittel |
WO1995024179A1 (en) * | 1994-03-11 | 1995-09-14 | The Procter & Gamble Company | LOW pH, HYDROLYTICALLY STABLE, COSMETIC COMPOSITIONS CONTAINING ACIDIC ACTIVES |
FR2718022B1 (fr) | 1994-04-01 | 1996-04-26 | Roussel Uclaf | Compositions cosmétiques ou dermatologiques et leur préparation. |
FR2722102B1 (fr) * | 1994-07-11 | 1996-08-23 | Cird Galderma | Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses |
US5843998A (en) | 1997-06-30 | 1998-12-01 | Song; Jin | Skin blemish treatment |
US6627215B1 (en) | 1998-12-30 | 2003-09-30 | Oligos Etc. Inc. | Devices for improved wound management |
US7868162B2 (en) * | 1998-12-30 | 2011-01-11 | Lakewood-Amedex, Inc. | Antimicrobial and antiviral compounds and methods for their use |
US20020032164A1 (en) | 1998-12-30 | 2002-03-14 | Dale Roderic M. K. | Antimicrobial compounds and methods for their use |
US6211349B1 (en) | 1998-12-30 | 2001-04-03 | Oligos Etc., Inc. | Protonated/acidified nucleic acids and methods of use |
US6211162B1 (en) | 1998-12-30 | 2001-04-03 | Oligos Etc. Inc. | Pulmonary delivery of protonated/acidified nucleic acids |
US6156294A (en) | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
AU2002337862A1 (en) * | 2001-10-18 | 2003-04-28 | Ilex Products, Inc. | Methods of treating skin with diphosphonate derivatives |
PL1620113T3 (pl) * | 2003-04-24 | 2011-10-31 | Galderma Sa | Formulacja iwermektyny do stosowania miejscowego do leczenia schorzeń dermatologicznych |
CN1687100A (zh) * | 2005-04-05 | 2005-10-26 | 奥林格斯技术有限公司 | 修饰性核苷酸及其用途 |
EP2149375A1 (en) | 2008-07-28 | 2010-02-03 | Despharma Kft. | Compositions for the treatment of dermatological diseases, and uses thereof |
WO2015075406A1 (en) | 2013-11-19 | 2015-05-28 | Lipopeptide Ab | New treatment of chronic ulcers |
FR3041540B1 (fr) | 2015-09-29 | 2018-10-26 | Galderma Research & Development | Composition nettoyante auto-moussante a rincer, contenant de l'ivermectine. |
-
2018
- 2018-06-12 MX MX2019014772A patent/MX2019014772A/es unknown
- 2018-06-12 EP EP18816615.1A patent/EP3638251B1/en active Active
- 2018-06-12 US US16/006,660 patent/US11096954B2/en active Active
- 2018-06-12 PT PT188166151T patent/PT3638251T/pt unknown
- 2018-06-12 FI FIEP18816615.1T patent/FI3638251T3/fi active
- 2018-06-12 BR BR122021011439-0A patent/BR122021011439B1/pt active IP Right Grant
- 2018-06-12 KR KR1020207000424A patent/KR20200014904A/ko active IP Right Grant
- 2018-06-12 KR KR1020237004991A patent/KR20230031370A/ko not_active Application Discontinuation
- 2018-06-12 BR BR112019026073-0A patent/BR112019026073B1/pt active IP Right Grant
- 2018-06-12 AU AU2018282905A patent/AU2018282905B2/en active Active
- 2018-06-12 EP EP23156658.9A patent/EP4241769A3/en active Pending
- 2018-06-12 DK DK18816615.1T patent/DK3638251T3/da active
- 2018-06-12 CA CA3066722A patent/CA3066722A1/en active Pending
- 2018-06-12 WO PCT/US2018/037151 patent/WO2018231863A1/en active Application Filing
- 2018-06-12 JP JP2019567981A patent/JP7148994B2/ja active Active
- 2018-06-12 CN CN201880038759.5A patent/CN110753549A/zh active Pending
-
2020
- 2020-07-30 US US16/943,939 patent/US20200360415A1/en not_active Abandoned
-
2021
- 2021-08-09 US US17/396,989 patent/US20210361689A1/en active Pending
-
2022
- 2022-09-02 AU AU2022224829A patent/AU2022224829A1/en active Pending
- 2022-09-15 JP JP2022147051A patent/JP7470449B2/ja active Active
- 2022-12-16 US US18/083,378 patent/US20230125677A1/en active Pending
-
2024
- 2024-04-05 AU AU2024202211A patent/AU2024202211A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2024202211A1 (en) | 2024-05-02 |
US20210361689A1 (en) | 2021-11-25 |
PT3638251T (pt) | 2024-05-22 |
EP3638251B1 (en) | 2024-03-06 |
US20180353529A1 (en) | 2018-12-13 |
AU2018282905A1 (en) | 2019-12-19 |
US20200360415A1 (en) | 2020-11-19 |
MX2019014772A (es) | 2020-02-07 |
BR112019026073B1 (pt) | 2021-11-03 |
JP7470449B2 (ja) | 2024-04-18 |
US11096954B2 (en) | 2021-08-24 |
KR20230031370A (ko) | 2023-03-07 |
KR20200014904A (ko) | 2020-02-11 |
BR112019026073A2 (pt) | 2020-06-30 |
BR122021011439B1 (pt) | 2022-03-29 |
WO2018231863A1 (en) | 2018-12-20 |
AU2018282905B2 (en) | 2022-06-02 |
EP3638251A1 (en) | 2020-04-22 |
CA3066722A1 (en) | 2018-12-20 |
JP2022183154A (ja) | 2022-12-08 |
US20230125677A1 (en) | 2023-04-27 |
EP4241769A2 (en) | 2023-09-13 |
EP4241769A3 (en) | 2023-11-08 |
EP3638251A4 (en) | 2021-03-10 |
CN110753549A (zh) | 2020-02-04 |
FI3638251T3 (fi) | 2024-04-29 |
JP7148994B2 (ja) | 2022-10-06 |
AU2022224829A1 (en) | 2022-09-29 |
JP2020523322A (ja) | 2020-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3478811T3 (da) | Rengøringssammensætninger og anvendelser deraf | |
DK3638251T3 (da) | Bisphosphocin gel formuleringer og brug deraf | |
DK3658557T3 (da) | Tyk2-inhibitorer og anvendelser deraf | |
DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
DK3607069T3 (da) | Produkter og sammensætninger | |
DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
DK3497094T3 (da) | Tlr7/8-antagonister og anvendelser deraf | |
DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
DK3580561T3 (da) | Hla-baserede metoder, sammensætninger og anvendelse heraf | |
DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
DK3655401T3 (da) | Tlr7/8-antagonister og anvendelser deraf | |
DK3668512T3 (da) | Pyruvatkinasemodulatorer og anvendelse deraf | |
DK3590924T3 (da) | Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf | |
DK3536698T3 (da) | Lanosterol-prodrugforbindelse og anvendelse deraf | |
DK3423076T3 (da) | Topisk cyclosporinholdige formuleringer og anvendelser deraf | |
DK3430129T3 (da) | Kolonidannende medium og anvendelse deraf | |
DK3621694T3 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
DK3434737T3 (da) | Modificerede pigmenter og deres anvendelse | |
DK3420039T3 (da) | Printningsformuleringer og fremgangsmåder | |
DK3743106T3 (da) | Influenzavirusvacciner og anvendelser deraf | |
DK3692009T3 (da) | Biocementationsfremgangsmåde og system | |
MA49905A (fr) | Polyesteramines et polyesterquats | |
DK3615502T3 (da) | Terapeutiske forbindelser og fremgangsmåder |